Patients presently usually survive burn injuries, despite their catastrophic origins. This is in part due to early excision and grafting, implementing critical care protocols, and providing nutritional and metabolic support. [1] [2] [3] [4] However, preventable death still occurs and is associated with tremendous impact on families and the health care system. To further improve outcomes, it is paramount to understand the major cause of death in burn patients. It was shown recently that the majority of patients who succumb to burn injury do so as a result of infection or sepsis, which ultimately leads to massive organ failure and death. 5, 6 Additionally, if survived, sepsis delays rehabilitation and patient recovery, substantially increases metabolic demands, and results in prolonged hospitalization. 7 The present approaches to predict sepsis via clinical scores or other biomarkers have yet to be successful.
Outside of the clinical definition of sepsis, quantification of biomarkers from susceptible patients' bloodwork has been traditionally accepted as a feasible alternative to predict sepsis. These markers are often biologic molecules, such as cytokines and chemokines, produced in response to microbial infections. Cytokines and chemokines are immunologic communication molecules that signal the body to activate its defense system to fight off invading pathogens. Examples of these proteins include tumor necrosis factors and various interleukins (ILs). 8 However, these approaches have been ineffective, as the window of time between the detection of these biomarkers and sepsis onset is extremely short. 9 Thus, no therapeutic intervention can be administered in time to "reverse" sepsis. Novel and reliable scoring that predicts sepsis well in advance of onset would allow patient-focused care for prevention to be based on a patient's immune-biochemical trajectory. More importantly, we hypothesize that it will promote novel therapeutic approaches and prospective clinical trials to be undertaken.
Previous work from our group delineated the activation of NLRP3 inflammasome in the white adipose tissue of thermally injured patients. 10 As NLRP3 expression is predominately observed in the myeloid population of immune cells, 11 we surveyed the most abundant tissue-derived myeloid population, macrophages, for NLRP3 inflammasome effector function. Specifically, we assessed white adipose-derived macrophage-specific IL-1β secretion via flow cytometry, as IL-1β is the effector cytokine produced by NLRP3 inflammasome assembly. 11 In this clinical study, we hypothesized that immune appraisal of burn patients at the first surgical intervention can reliably identify patients susceptible to sepsis, which subsequently develops during hospitalization. The advantages of utilizing this approach are that it is more stable and provides a more accurate depiction of immune status in comparison to short-lived blood-based markers.
Methods

Patient cohort and study protocol
This study was approved and performed in accordance with the guidelines and regulations of the Research Ethics Board, Sunnybrook Health Sciences Centre (REB#: 194-2010). Informed consent was obtained from patients or from their substitute decision makers. A total of 37 thermally injured adult patients (≥18 years old) with total burn surface area >20% admitted to our burn center between 2013 and 2015 were enrolled in the study (Supplemental Fig S1) , indiscriminate of sex or age. Adipose tissue and blood plasma samples from these patients were collected within 96 hours after thermal injury, and biomarkers were measured from both specimens to generate an acute immune profile post thermal injury. Patients' clinical outcomes and complications were followed and documented until time of hospital discharge (Table) . Control adipose tissues (normal) were obtained from donors who had undergone plastic surgery for tissue reconstruction and used to compare burn patients to normal tissue (n = 12; mean age = 44; males = 58%). Sepsis was defined prospectively by the staff burn surgeons based on the clinical presentation of the patient and in accordance with the American Burn Association guidelines as well as new Critical Care Guidelines (Sepsis-3).
12,13
Harvesting of stromal vascular fractions from white adipose tissue Excised adipose specimens from burned patients were immediately transferred to the laboratory, where they were digested with collagenase (Sigma, St. Louis, MO) at 1 mg/mL in serum-free RPMI1640 in a shaking incubator for 2 hours at 37°C. The digest was then strained through sterile gauze to remove particulates, and the cell fraction was collected by centrifugation. The cell pellets were washed multiple times with Hank's Balanced Salt Solution, resuspended in Hank's Balanced Salt Solution, and red blood cells were removed by density centrifugation with Lympholyte H (Cedarlane, Burlington, ON), following the manufacturer's protocol. The cell suspension was then passed through a 100 micron strainer (BD Biosciences, Mississauga, ON) and cells were counted.
Sample staining and flow cytometry
Stromal vascular fraction (SVF)-derived leukocytes were stained with monoclonal antibodies on ice for 25 minutes, followed by washing, and were analyzed using BD LSR II Special Order System (BD Biosciences, San Jose, CA). Cells were gated on FSC-A and SSC-A, followed by doublet exclusion (FSC-W x FSC-H, SSC-W x SSC-H). The percentage leukocytes, monocytes/macrophages, T-cells, and IL-1β-producing leukocytes in the stromal vascular fraction were identified using the following flurochrome-conjugated antibodies: anti-CD45 (Brilliant Violet 510, Biolegend, San Diego, CA), anti-CD14 (PE, eBiosciences, San Diego, CA), anti-CD16 (Anti-Human CD16 Alexa Fluor 700, eBiosciences), anti-CD3 (PE.Cy7, eBiosciences), and anti-IL-1β (Alexa Fluor 647, Biolegend), in accordance with the manufacturer's flow cytometry protocol.
All analysis was conducted in an unbiased manner and without any prior knowledge of patient classification (nonsepsis or sepsis). Our primary analysis compared the acute immunologic profile at the site of injury between patient cohorts that became septic versus nonseptics via flow cytometry. Briefly, leukocytes purified from the SVF were analyzed for cellular heterogeneity and capacity to produce inflammatory cytokines, namely IL-1β. The gating strategy is outlined in Supplemental Fig S2 , where leukocytes were initially gated based on granularity and CD45 (side scatter x CD45), followed by size (forward scatter). These gated cells were then stained for cell surface markers for monocytes and macrophages (CD14 hi CD16 lo ). Finally, CD14 hi cells were assessed for IL-1β positivity, indicating the capacity of these cells to produce this inflammatory cytokine.
Plasma sample preparation and luminex
EDTA-anticoagulated samples were drawn within 96 hours after thermal injury and processed using a standard Percoll-based PBMC isolation from periphery. Plasma samples from nonseptic and septic patients were used to compare anti-inflammatory trajectories for IL-10 and IL-1 receptor antagonist (RA) using a Multiplex platform (Millipore, MA). Experimental kits were all conducted in accordance with manufacturers' protocol. Raw data were processed using Millipore Analyst software. All values are presented as mean ± SEM and expressed in pg/mL.
Statistical analysis
All data was analyzed by 1-and 2-way analysis of variance (ANOVA) with a Tukey post-hoc test used when ≥2 groups were present. Correlations were conducted using Pearson 2-tailed tests to explore the association between Septic Predictor Index (SPI: percentage IL-1β produced by leukocytes/macrophages in the SVF) and sepsis onset (days postburn). All graphs were created using GraphPad Prism 6.0 (San Diego, CA) and analyzed statistically using SPSS 20 (IBM Corp., New York, NY). 
Results
Immunologic profile of burned patients assessed by flow cytometry at the injury site
As described in the methods section, the gating strategy for flow cytometric data is outlined in Supplemental Fig S2. The patient cohort that eventually developed sepsis exhibited less macrophage population (CD14 hi CD16 lo cells) at the site of injury in contrast to nonseptic patients (mean = 8.7 ± 1.4 vs 29.3 ± 5.5; P < .05; Fig 1, A) , within 96 hours post thermal injury. However, a greater percentage of these macrophages at the site of injury from patients who eventually became septic were pro-inflammatory IL-1β+, whereas there were very few IL-1β+ macrophages in the nonseptic patients post burn (sepsis: 16.3 ± 3.9 vs nonsepsis: 2.4 ± 0.74; P < .01; Fig 1, B) . This relationship was also observed when septic patients were compared with controls for SVF macrophages and IL-1β+ cells (P < .05 and P < .001, respectively).
Systemic immunologic profile of burned patients
We subsequently assessed systemic biomarkers in plasma samples from burn patients via multiplex. Anti-inflammatory cytokines IL-10 and IL-1RA exhibited significant differences between the septic and nonseptic patient cohorts (Fig 2, A and B) . Specifically, the septic cohort had a significantly higher mean concentration detected in plasma in comparison to the nonseptic group for both IL-10 (249 ± 68 vs 28 ± 5.7 pg/mL; P = .017) and IL-1RA (183 ± 28 vs 89 ± 18 pg/mL; P = .014). These observations also were consistent when comparing septic patients and controls.
Septic predictor index
To simplify this technique, we created a ratio of the aforementioned IL-1β from SVF-derived macrophages and macrophage proportion (proportion of CD14+ IL-1β+ cells / proportion of CD14 hi CD16 lo cells). This was arbitrarily labeled as the "Septic Predictor Index." Septicemia patients had significantly greater immune status ratios relative to both normal (mean = 3.3 ± 0.9 vs 0.09 ± 0.02; P < .01) and nonsepsis burn patients (mean = 3.3 ± 0.9 vs 0.17 ± 0.05; P < .01; Fig 3, A) . All septic patients had ratios >0.5 (whereas all nonseptic patients had SPI < 0.5). Interestingly, when SPI ratios were plotted as a function of time we saw that patients with a ratio >1 all had sepsis occur within 12 days post injury, whereas patients with ratios between 0.5-1 had sepsis onset after 12 days (Fig 3, B) . Using a Pearson correlation, this association between SPI and sepsis onset was negatively correlated (r = −0.71, P = .0013).
We previously reported that elderly burn patients have delayed immune responsiveness after injury compared to adult counterparts 14, 15 ; thus, we wanted to determine if these observations were attributed to an age-effect. Patients were classified as elderly (≥65 years of age), as defined by the National Institute of Health and World Health Organization. When comparing SPI values, no significant differences were found between adult and elderly septic patients (Fig 4, A) . However, the SPI revealed a similar trend in both adults and elderly that was apparent after stratifying patients into nonsepsis and sepsis groups. Extending this analysis, similar results were obtained when septic and nonseptic patients were stratified based on survivorship (Fig 4, B) . These findings indicate that the different immune measures at the site of injury observed 96 hours post-burn are exclusive to septicemia prediction and not confounded by age or mortality. Lastly, when comparing the onset of sepsis, it was observed that late onset sepsis had significantly lower survival than early onset sepsis (Mantel-Cox = 4.21, P = .040; Supplemental Fig S3) .
Discussion
This study successfully identified a novel technique that can be used to identify patients susceptible to sepsis by examining excised adipose tissue at the first surgical intervention occurring within 96 hours after injury. Septic patients had reduced macrophage proportion in the SVF, yet a great proportion of these innate immune cells stained positive for intracellular proinflammatory IL-1β. Taken together, these observations were used to create the SPI ratio of determining septicemia in adult burn patients. The importance of this study is that it could enable healthcare providers to implement interventions of all types (e.g., surgical, pharmacologic) a priori to fight the occurrence of sepsis that occurs later. Despite the relevance being clear, its utility requires further exploration and validation.
In this study, we primarily focused on the immune response elicited at the site of injury post burn as the first indicator of sepsis susceptibility. In contrast to conventional plasma biomarkers, assessing the site of injury embodies spatial precision via a highly specific profile localized to the wound area. This differs from biomarkers measured from the bloodstream that have an were obtained from healthy donors. Data expressed as mean ± SEM. *P < .05, **P < .01, and ***P < .001, respectively. undecipherable origin. At the site of injury, we observed a reciprocal relationship of macrophage abundance and IL-1β secretion between the nonseptic and septic cohorts. In the septic cohort, fewer macrophages were present at the site of injury, yet a great proportion of these cells were IL-1β+ relative to nonseptic counterparts. This observation was consistent with our previous report of increased caspase-1 activity (a by-product of NLRP3 inflammasome activation that cleaves IL-1β into its mature form) in the SVF after thermal injury. 10, 11 Although increases in macrophages at the site of injury have been shown in the past, 16 presently we demonstrate that these increases occurring within the first 96 hours are unique to nonsepsis patients. Thus, the imbalanced immune trajectory in sepsis patients may be a compensatory mechanism. Individual macrophages must exert greater function, and this high demand in IL-1β production from a limited number of macrophages can progress to immune exhaustion quickly, which renders a patient incapable of fending off future infections. This hypothesis also was supported by a recent study that showed elderly burn patients have delayed immune activity followed by a hyperactive immune response, which ultimately results in consequential immune paralysis. 14, 15 Extending this notion of immune inadequacy, animal models of sepsis have demonstrated that "immune-priming" or the administration of a moderate immune challenge using an endotoxin such as lipopolysaccharides (LPS) prior to subsequent infection results in increased bacterial clearance and overall survival. 17 Although flow cytometry is not the standard assay to determine cytokine secretion (as it does not measure cytokine concentration), it is an acceptable method to deduce origin of cytokine production. Often, intracellular staining of cytokines is done after the application of golgi plug, a protein transport inhibitor to the sample of interest. Treating samples with golgi plug typically takes 6 hours, which is the time needed to ensure that the cytokine is made in these and thus becomes detectable, but not secreted. Interestingly, data presented in this study are patient samples without golgi plug treatment and exhibited no overt differences when compared with unpublished data where samples were treated with golgi plug followed by staining. Thus, we eliminated the use of golgi plug to this procedure, as it conserves 6 hours in the overall turnaround time to measure the data required for the SPI, further supporting the clinical feasibility of this technique.
The immune stimulatory aspect of treating critically ill and burn patients is not novel and has been investigated for quite some time. For example, trials have shown that the administration of granulocyte-colony stimulating factor and granulocyte-macrophage , whereas late onset sepsis were between 0.5-1. Thus, the magnitude of the SPI predicted acute or delayed sepsis onset. Data expressed as mean ± SEM. *P < .05, **P < .01, and ***P < .001, respectively.
Fig 4.
Analysis of the immunologic profiles of burned patients stratified by age and mortality. Frequency of IL-1β produced by the macrophage and macrophage proportion at the site of injury is expressed as a quotient to generate the SPI (the proportion of CD14+ IL-1β+ cells/proportion of CD14 hi CD16 lo cells). The immune status ratio was stratified based on (A) age and (B) mortality revealing that albeit different, septic burn patients behaved similarly regardless of age or survivorship. Data expressed as mean ± SEM. *P < .05, *P < .01, and P < .001, respectively. colony-stimulating factor can stimulate inflammation and the immune system. [18] [19] [20] [21] However, despite its acute benefit to leukocyte and neutrophil expansion, these studies failed to demonstrate a therapeutic benefit in trauma-induced sepsis and other complications. Similarly, numerous studies in rodents have demonstrated that treatment with Flt3 ligand stimulates immune response at the wound and increases bacterial clearance and survival. 22, 23 However, despite its promise, the clinical benefit remains unknown.
The intriguing finding of the smaller macrophage population observed at the site of injury from the septic cohort may be explained by anti-inflammatory cytokines circulating in the bloodstream. The present study showed heightened anti-inflammatory cytokines in plasma of septic patients. It has been shown that IL-10 and IL-1RA not only have antagonizing effects on IL-1β, but they also dampen the immune response by preventing leukocyte trafficking. [24] [25] [26] Therefore, the elevated IL-10 and IL-1RA levels in septic patients may explain the diminished abundance of macrophages at the site of injury. The trigger for the aberrant production of anti-inflammatory cytokines, which leads to the prevention of macrophage recruitment to the site of injury in septic patients remains unknown. We postulate that a potential cause of this phenomenon may be attributed to the dual role of IL-6: both as a cytokine, and a myokine or energy0sensing soluble factor.
27-29 IL-6 has been shown to be highly elevated after exercise and induces a systemic antiinflammatory state. 30, 31 The observed overactivation of inflammation at the site of injury may counteract the systemic state and consequently lead to the immune exhaustion phenotype that we propose in this study.
Although the class of infection (gram-positive and gramnegative) presents a differential clinical course in burn patients, 32, 33 infections from both bacterial origins yielded similar alterations in immune profiles within patient cohorts. It is essential to recognize that this approach of early appraisal at the site of injury addresses the immune profile of patients in response to burn and does not determine invading microbes themselves. Although the source of the sepsis is not entirely clear, in burn patients sepsis generally originates from a burn wound infection and develops into pneumonia and subsequent complications. [34] [35] [36] This was supported in our study, in which pneumonia occurred in 75% of septic patients, whereas in nonsepsis burns it accounted for a 29% incidence (Table) . However, further elaborating on our present profiling in terms of complications is beyond the scope of the present study.
Despite the clear utility and successful identification of a novel predictor of sepsis, the authors would like to note a few limitations of the present study. Although all septic patients showed a consistent phenotype, this study was conducted at a single center with a relatively small sample size; a larger sample size would enable true sensitivity and specificity in order to highlight its clinical utility. Also, prior to the implementation of the SPI to burn care providers and therapeutic clinical trials, a prospective validation study will ultimately be required. The present study investigated adipose tissue from the site and injury and although it would have been interesting to compare samples from other remote regions, this was not feasible. However, we recently showed in a rodent study of burn-sepsis that even epididymal adipose tissue has the same immune and inflammatory response as the site of injury (unpublished data). Presently, the SPI was able to identify sepsis and nonsepsis groups regardless of bacteremia; however, future studies should investigate whether the SPI is able to distinguish systemic inflammatory response syndrome from sepsis to broaden its therapeutic scope.
In conclusion, the present study highlights a rapid and efficient approach to individually appraise the immune system in order to identify patients susceptible to future sepsis onset. There are various approaches that have been shown to alleviate the hypermetabolic response in burn patients [37] [38] [39] [40] ; however, there is a lack of targeted therapy that targets an individual cell population to alter its trajectory to bypass detrimental outcomes. Future studies should extend our findings and focus on fine-tuning the immunemetabolic dynamic such that patients could simultaneously maintain both a functional metabolic and immune system after thermal injury to elicit appropriate protection against microbial infections and sepsis.
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